Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedApr 24, 2013LevoxylChemical contamination: emission of strong odor after package was opened.Pfizer Inc. · D-256-2013Class IITerminatedApr 24, 2013LevoxylChemical contamination: emission of strong odor after package was opened..Pfizer Inc. · D-255-2013Class IITerminatedApr 24, 2013LevoxylChemical contamination: emission of strong odor after package was opened..Pfizer Inc. · D-254-2013Class IITerminatedApr 24, 2013LevoxylChemical contamination: emission of strong odor after package was opened.Pfizer Inc. · D-253-2013Class IITerminatedApr 24, 2013LevoxylChemical contamination: emission of strong odor after package was opened.Pfizer Inc. · D-252-2013Class IITerminatedApr 24, 2013LevoxylChemical contamination: emission of strong odor after package was opened..Pfizer Inc. · D-251-2013Class IITerminatedApr 24, 2013Children's Acetaminophen Oral SuspensionLabeling: Not Elsewhere Classified: This unit dose product is being recalled because the product's name includes the word "Children's" which is misleading since the 650...Precision Dose Inc. · D-250-2013Class IITerminatedApr 24, 2013CopaxonePresence of Foreign Substance: Product is being recalled due to receiving an elevated number of patient complaints related to a visible presence of medical grade...Teva Pharmaceuticals USA, Inc. · D-249-2013Class IIITerminatedApr 24, 2013buPROPion Hydrochloride Extended-Release TabletsFailed USP Dissolution Test Requirements: Out-of-specification dissolution results at the 8 hour stability testing point.Actavis South Atlantic LLC · D-248-2013Class IITerminatedApr 17, 2013Cefdinir for Oral SuspensionDefective Container: This recall is being carried out due to the potential for improperly sealed bottles.Teva Pharmaceuticals USA, Inc. · D-247-2013Class IIITerminatedApr 17, 2013JolessaFailed Tablet/Capsule Specifications: This recall is being carried out due to an out of specification result for appearance.Teva Pharmaceuticals USA, Inc. · D-246-2013Class IIITerminatedApr 17, 2013Portia (levonorgestrel and ethinyl estradiol) TabletsFailed Tablet/Capsule Specifications: This recall is being carried out due to an out of specification result for appearance.Teva Pharmaceuticals USA, Inc. · D-245-2013Class IITerminatedApr 17, 2013LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETSPresence of Foreign Substance: Reports of gray smudges identified as minute stainless steel particulates were found in the recalled tablets by the manufacturerGsms · D-244-2013Class IITerminatedApr 10, 20130.9% Sodium Chloride InjectionLack of Assurance of Sterility: The product is being recall due to the product lot being incorrectly released without meeting product specifications. There is the...Hospira Inc. · D-243-2013Class IITerminatedApr 10, 2013Ethambutol Hydrochloride TabletsSubpotent Drug: Out Of Specification results for assay at the stability time-point of 24 months.West-ward Pharmaceutical Corp. · D-242-2013Class IIITerminatedApr 10, 2013Fougera Ketoconazole Cream 2%Failed Impurities/Degradation Specifications: Ketoconazole Cream 2% is the subject of a voluntary drug recall by Fougera due to an Out Of Specification result for an...Fougera Pharmaceuticals Inc. · D-241-2013Class IIITerminatedApr 10, 2013TEV-TROPINLabeling: Label Mix-up: Units of Lot 201131320087 are packaged in cartons labelled for Needle-Free Head B, but contaiin Needle-Free Head AFerring Pharmaceuticals Inc · D-240-2013Class IITerminatedApr 10, 2013Amoxicillin for Oral SuspensionMicrobial Contamination of Non-Sterile Products: Suspensions made from these lots of Amoxicillin 125 mg/5 mL showed yeast and mold growth at the 14 day time point.Dr Reddys Laboratories Tennessee LLC · D-239-2013Class IIITerminatedApr 10, 2013Tizanidine Tablets USPLabeling Illegible: There is a possibility that the bottle labels do not contain the strength of the product as well as other printing details.Dr. Reddy'S Laboratories · D-238-2013Class IITerminatedApr 10, 2013CLONAZEPAM ORALLY DISINTERGRATING TabletsFailed Content Uniformity Specifications: Recall is being carried out due to an out-of-specification result for content uniformity.Teva Pharmaceuticals USA, Inc. · D-237-2013Class IITerminatedApr 10, 2013Oxiracetam & CholineMarketed Without an Approved NDA/ANDA: The products are unapproved drugsPalmer Natural Products · D-236-2013Class IITerminatedApr 10, 2013BoostYourGrade.comMarketed Without an Approved NDA/ANDA: The products are unapproved drugsPalmer Natural Products · D-235-2013Class IITerminatedApr 10, 2013Brain DefoggerMarketed Without an Approved NDA/ANDA: The products are unapproved drugsPalmer Natural Products · D-234-2013Class IITerminatedApr 10, 2013Piracetam & CholineMarketed Without an Approved NDA/ANDA: The products are unapproved drugsPalmer Natural Products · D-233-2013Class IITerminatedApr 10, 2013Aniracetam and CholineMarketed Without an Approved NDA/ANDA: The products are unapproved drugsPalmer Natural Products · D-232-2013Class IITerminatedApr 10, 2013NOOTROPA COGNITIVE ENHANCEMENT SUPPLEMENTMarketed Without an Approved NDA/ANDA: The products are unapproved drugsPalmer Natural Products · D-231-2013Class IITerminatedApr 10, 2013Aniracetam & Choline capsulesMarketed Without an Approved NDA/ANDA: The products are unapproved drugsPalmer Natural Products · D-230-2013Class IITerminatedApr 3, 2013FREPP/SEPP Kit containing 1 FREPPLabeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.CareFusion 213, LLC · D-229-2013Class IITerminatedApr 3, 2013Donor Prep Kit containing 1 FREPPLabeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.CareFusion 213, LLC · D-228-2013Class IITerminatedApr 3, 2013Blood Culture Prep Kit II containing 1 FREPPLabeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.CareFusion 213, LLC · D-227-2013Class IITerminatedApr 3, 2013SEPP 10% Povidone Iodine Solution USPLabeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.CareFusion 213, LLC · D-226-2013Class IITerminatedApr 3, 2013SEPP 2% Iodine Tincture USPLabeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.CareFusion 213, LLC · D-225-2013Class IITerminatedApr 3, 2013SEPP 70% IsopropanolLabeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.CareFusion 213, LLC · D-224-2013Class IITerminatedApr 3, 2013Propofol Injectable EmulsionPresence of Particulate Matter: Visible particulate embedded in vials was observed and confirmed in a sample bottle during retain inspection.Hospira Inc. · D-223-2013Class IITerminatedApr 3, 2013PHYSICIANS TOTAL CAREPresence of Foreign Substance(s): There is a potential for foreign particulate matter in the API.Physicians Total Care, Inc. · D-222-2013Class IITerminatedApr 3, 2013PHYSICIANS TOTAL CAREPresence of Foreign Substance(s): There is a potential for foreign particulate matter in the API.Physicians Total Care, Inc. · D-221-2013Class IITerminatedApr 3, 2013Ciprofloxacin Tablets USPPresence of Foreign Substance(s): A complaint was received for a rubber-like material in a 500 mg Ciprofloxacin tablet.West-ward Pharmaceutical Corp. · D-220-2013Class IIITerminatedApr 3, 2013TORISEL KitLack of Assurance of Sterility; potential that a low level of endotoxins may be present in the diluent vials.Pfizer Inc. · D-219-2013Class IIITerminatedApr 3, 2013Derma-Smoothe/FSSubpotent; 22 month stability timepointHill Dermaceuticals, Inc. · D-218-2013Class IIITerminatedApr 3, 2013Derma-Smoothe/FSSubpotent; 12 month stability timepointHill Dermaceuticals, Inc. · D-217-2013